Efficacy and Safety of ASF1057 in the Treatment of Seborrhoeic Dermatitis

Summary

A growing body of evidence supports the hypothesis that the pathophysiology of seborrhoeic dermatitis has a potentially causative neurogenic inflammatory aspect. ASF1057 is a new drug that acts through a modulation of neurogenic inflammation through important complementary mechanisms of action. This study will test the efficacy and safety of ASF1057 in the treatment of patients with seborrhoeic dermatitis.

Timeline

Start

2007-12

Primary completion

2008-05

Completion

2008-06

Drugs

Indications